Literature DB >> 7685640

Homogeneous production of feline interferon in silkworm by replacing single amino acid code in signal peptide region in recombinant baculovirus and characterization of the product.

Y Ueda1, T Sakurai, A Yanai.   

Abstract

In a previous paper we reported that we constructed a recombinant baculovirus named BmFeIFN1 which produced recombinant feline interferon (FeIFN) in silkworm after infection. High purification of FeIFN in body fluid from the larvae revealed that two kinds of FeIFN were produced by the BmFeIFN1. The difference between the two in the NH2-terminal amino acid sequence was clarified, and two kinds of processing at different sites in FeIFN precursor were suggested. Changing one residue of the amino acid sequence in deduced signal peptide by site directed mutagenesis of encoding cDNA led to the production of homogeneous FeIFN whose NH2-terminal three amino acid sequence was identical to the conserved sequence of human interferon-alpha. We designated the FeIFN produced as rFeIFN. Amino acid sequence analysis revealed that rFeIFN consisted of 170 amino acid residues. The COOH-terminal amino acid of the rFeIFN is Glu which is located at one amino acid residue upstream to the COOH-terminal amino acid deduced from the nucleotide sequence. Positive periodic acid Schiff reaction, undetectability of Asn at position 79 by automated protein sequencer, and detectability of N-acetylglucosamine not N-acetylgalactosamine suggested that rFeIFN was N-glycosylated. rFeIFN was stable at pH 1.5 at 4 degrees C for at least 50 days, and had an antiviral action on feline calicivirus or feline herpesvirus in vitro. Its isoelectric point was pI 6.5. Comparing the structure and biosynthesis of rFeIFN with those of HuIFNs, rFeIFN may be classified as omega-type.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7685640     DOI: 10.1292/jvms.55.251

Source DB:  PubMed          Journal:  J Vet Med Sci        ISSN: 0916-7250            Impact factor:   1.267


  10 in total

1.  Antiproliferation and colony-forming inhibition activities of recombinant feline interferon (rFeIFN) on various cells in vitro.

Authors:  B P Priosoeryanto; S Tateyama; R Yamaguchi; K Uchida
Journal:  Can J Vet Res       Date:  1995-01       Impact factor: 1.310

2.  Novel recombinant feline interferon carrying N-glycans with reduced allergy risk produced by a transgenic silkworm system.

Authors:  Sachi Minagawa; Yuzuru Nakaso; Masahiro Tomita; Takenori Igarashi; Yoshio Miura; Hideyo Yasuda; Satoshi Sekiguchi
Journal:  BMC Vet Res       Date:  2018-08-31       Impact factor: 2.741

3.  The innate antiviral immune system of the cat: molecular tools for the measurement of its state of activation.

Authors:  Céline Robert-Tissot; Vera L Rüegger; Valentino Cattori; Marina L Meli; Barbara Riond; Maria Alice Gomes-Keller; Andrea Vögtlin; Burghardt Wittig; Christiane Juhls; Regina Hofmann-Lehmann; Hans Lutz
Journal:  Vet Immunol Immunopathol       Date:  2011-06-12       Impact factor: 2.046

4.  Use of recombinant interferon omega in feline retrovirosis: from theory to practice.

Authors:  Ana Doménech; Guadalupe Miró; Victorio M Collado; Natalia Ballesteros; Leticia Sanjosé; Elena Escolar; Sonsoles Martin; Esperanza Gomez-Lucia
Journal:  Vet Immunol Immunopathol       Date:  2011-06-12       Impact factor: 2.046

Review 5.  Feline infectious peritonitis.

Authors:  Katrin Hartmann
Journal:  Vet Clin North Am Small Anim Pract       Date:  2005-01       Impact factor: 2.093

6.  Characterization of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori).

Authors:  Minoru Tada; Ken-ichiro Tatematsu; Akiko Ishii-Watabe; Akira Harazono; Daisuke Takakura; Noritaka Hashii; Hideki Sezutsu; Nana Kawasaki
Journal:  MAbs       Date:  2015-08-11       Impact factor: 5.857

7.  Use of recombinant feline interferon and glucocorticoid in the treatment of feline infectious peritonitis.

Authors:  T Ishida; A Shibanai; S Tanaka; K Uchida; M Mochizuki
Journal:  J Feline Med Surg       Date:  2004-04       Impact factor: 2.015

8.  Evaluation of inflammation and immunity in cats with spontaneous parvovirus infection: consequences of recombinant feline interferon-omega administration.

Authors:  Saverio Paltrinieri; Alessia Crippa; Teodora Comerio; Andrea Angioletti; Paola Roccabianca
Journal:  Vet Immunol Immunopathol       Date:  2007-04-19       Impact factor: 2.046

9.  Adjuvant immunotherapy of feline fibrosarcoma with recombinant feline interferon-omega.

Authors:  Verena Hampel; Bianca Schwarz; Christine Kempf; Roberto Köstlin; Ulrike Schillinger; Helmut Küchenhoff; Nora Fenske; Thomas Brill; Johannes Hirschberger
Journal:  J Vet Intern Med       Date:  2007 Nov-Dec       Impact factor: 3.333

10.  Structural insight and stability of TNFR-Fc fusion protein (Etanercept) produced by using transgenic silkworms.

Authors:  Masato Kiyoshi; Ken-Ichiro Tatematsu; Minoru Tada; Hideki Sezutsu; Hiroko Shibata; Akiko Ishii-Watabe
Journal:  J Biochem       Date:  2021-02-06       Impact factor: 3.387

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.